Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.
about
Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancerThe hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disordersSpotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to datePathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus ErythematosusThe effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics.Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey.Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy.Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys.Transport of anti-IL-6 antigen binding fragments into cartilage and the effects of injury.Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis.Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013Sirukumab: A Potential Treatment for Mood Disorders?Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6.Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritisAberrant B-lymphocyte responses in lupus: inherent or induced and potential therapeutic targets.Tocilizumab in pediatric rheumatology: the clinical experience.Monoclonal antibody treatments for rheumatoid arthritis.Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs.Sirukumab : a novel therapy for lupus nephritis?New treatments for inflammatory rheumatic disease.Novel investigational drugs targeting IL-6 signaling for the treatment of depression.Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.IL-6 blockers in systemic onset juvenile idiopathic arthritis.The safety of pharmacological treatment options for lupus nephritis.Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials.Advances in the treatment of cutaneous lupus erythematosus.Sirukumab: a promising therapy for rheumatoid arthritis.An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo.Functions of interleukin-34 and its emerging association with rheumatoid arthritis.Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.Ethnic sensitivity assessment - pharmacokinetic comparability between Japanese and non-Japanese healthy subjects on selected mAbs.Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach.Absolute Bioavailability and Pharmacokinetic Comparability of Sirukumab Following Subcutaneous Administration by a Prefilled Syringe or an Autoinjector.Investigational drugs in systemic vasculitis.Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study.Deciphering the In Vivo Performance of a Monoclonal Antibody to Neutralize Its Soluble Target at the Site of Action in a Mouse Collagen-Induced Arthritis Model.Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients.
P2860
Q26769917-3561CC8E-6B01-4C93-BEEF-2A3503320521Q26823465-88958FE7-2297-422D-BBA3-E5909B6EFB34Q28076558-BBD11D44-E983-409C-948C-B04567559A51Q28088753-068E1714-2E7F-45AE-BE7E-AF42AC335CD7Q30566003-710B1CF1-FA89-4CBE-BB0B-A1A2489D63B0Q31091923-32C4F761-7198-410D-BD26-7A909CE062E3Q35582297-D26FDCFD-DC75-4369-BAE3-CAC977E03A1FQ36579912-89E1BD38-FFEB-4D4A-B7E6-B25D509008A1Q36681123-5DB5DB2D-DC85-4861-8B85-05458398AC09Q37331009-73C3289C-85BF-4F55-B5FC-F64C6D2563E2Q37456300-0685EBB4-2C0D-4D6C-8A15-55664DAA6208Q37496388-C5A46376-91EA-411E-87E4-1EE15593D238Q37562443-5B124A87-50CC-4E28-BA0D-A655D39EE4C1Q37600383-DEA4531E-A6ED-41C9-83C7-D669D5C9CFE4Q38091288-AB0D921E-4B29-47EC-A992-180E7CB502D8Q38108851-8905AAB2-50A8-4AA6-9397-F79AAECD2D5CQ38110210-89BF8649-6E3B-4880-BC34-26A0732DF20AQ38116065-9CEAB522-13A2-49F9-A124-631BB410681CQ38207142-93528459-3E21-47E6-B871-0956FAF48C93Q38246130-AB4A02ED-8568-4789-8DDD-BF8E26831B48Q38266252-5F94D4F0-2BD7-4F96-96DF-93E1DCB26899Q38317241-18A8485C-5236-43F9-891A-041252DF0D43Q38371450-89CB5EAA-DDD2-476D-9DE9-CAE48F879BDEQ38661146-0424C957-235B-494D-8CB7-D309CD096271Q38829637-176E0FDC-D302-47FB-A417-5DF477B3E4BEQ38840646-AEA4315D-7A9A-4A9A-8BDB-B1F3CCDA2EF6Q38851093-2341CD78-A36A-44EF-ABCE-76F110A3C2A0Q38856800-21F22EFE-2696-496E-BA09-4FF2F408F440Q38931171-E114A398-DB67-4585-B6BA-256D6881735EQ38934355-FFB83C83-16EC-4677-B275-2EEDEBD7843DQ39218839-39EEC883-2F79-4390-9420-9741DDC50615Q41676322-21857586-1547-4D0F-A179-4748498774CCQ46523280-F187717C-EF9E-49CD-AC6A-F35B19542A1AQ47109861-9FA06A19-24C8-455F-B172-74E71FCB9B44Q47692758-BBBF92A1-F962-43D2-A84A-3D5CF921B31CQ50973039-B1444118-0512-403D-A5EE-F0D54F483D93Q51834131-6BA635CC-5F00-4890-B2DA-3E223E444B37Q52874195-48C503E5-6276-43BE-8E42-AFBECD7DA52FQ53224491-BFFA2E69-D5A5-47D5-88D7-05B3EBA1745CQ55417294-28FF7E4E-681F-433C-AF05-12926DAA05A0
P2860
Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Pharmacokinetics, pharmacodyna ...... cts in a first-in-human study.
@ast
Pharmacokinetics, pharmacodyna ...... cts in a first-in-human study.
@en
type
label
Pharmacokinetics, pharmacodyna ...... cts in a first-in-human study.
@ast
Pharmacokinetics, pharmacodyna ...... cts in a first-in-human study.
@en
prefLabel
Pharmacokinetics, pharmacodyna ...... cts in a first-in-human study.
@ast
Pharmacokinetics, pharmacodyna ...... cts in a first-in-human study.
@en
P2093
P2860
P1476
Pharmacokinetics, pharmacodyna ...... cts in a first-in-human study.
@en
P2093
Bart Frederick
Bart Van Hartingsveldt
Craig Comisar
Esther Bouman-Thio
Honghui Zhou
Hugh M Davis
Joseph C Marini
Zhenhua Xu
P2860
P304
P356
10.1111/J.1365-2125.2011.03964.X
P407
P577
2011-08-01T00:00:00Z